EPO and chronic kidney disease: CKD patients on EPO therapy have shown signs of cardiovascular improvement and reversal of left ventricular hypertrophy (Goldberg et al., 1992; Frank et al., 2004), suggesting that correction of anemia may prevent progression of HFpEF.